Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet (E484K, K417N/T, and N501Y), which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine-induced antibody responses than B.1.351, suggesting that changes outside the receptor-binding domain (RBD) impact neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants despite interacting with two of the ACE2-binding site mutations. We explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.

Original publication

DOI

10.1016/j.cell.2021.03.055

Type

Journal article

Journal

Cell

Publication Date

27/05/2021

Volume

184

Pages

2939 - 2954.e9

Keywords

P.1, RBD, SARS-CoV-2, VH3-53, antibody, escape, neutralization, spike, structure, variant, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Binding Sites, COVID-19, Cell Line, Humans, Immune Evasion, Immunization, Passive, Mutation, Protein Binding, Protein Domains, SARS-CoV-2, Sequence Deletion, Spike Glycoprotein, Coronavirus, Vaccination, Vaccines, COVID-19 Serotherapy